Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

929 questions · 946 findings · 295 reviews · Headline outcomes only

No studies found 150 · 15.9%GRADE not reported 47 · 5%Very low 312 · 33%Low 262 · 27.7%Moderate 138 · 14.6%High 37 · 3.9%

Topical anesthetics vs placebo or no intervention

Episodes of apnea · lumbar puncture in newborn infants

It is very uncertain whether topical anesthetics changes apnea: occurrence of one or more episodes№ of LPs: 100(1 quasi‐RCT) compared with placebo or no intervention (very low certainty).

1 finding from 1 review

Early vs delayed mobilisation

Self‐reported shoulder function: Croft Shoulder Disability Score (1 or more problems) · adults with minimally displaced or displaced (2‐part or 3‐part) proximal humeral fractures treated non‐surgically (5 trials)

It is very uncertain whether early changes self‐reported shoulder function: Croft Shoulder Disability Score (1… compared with delayed mobilisation (very low certainty).

2 findings from 1 review

Summary of findings: anti‐pseudomonal antibiotics vs placebo

Frequency of hospital admissions for pulmonary exacerbations ‐ not measured · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: anti‐pseudomonal antibiotics may leads to lower pulmonary exacerbations: frequency of one or more hospital admissions compared with placebo (low certainty).

1 finding from 1 review

NSAIDs vs placebo or active control

Visual improvement at end of treatment, as defined by two or more Snellen lines · participants with acute CME (< 4 months) following cataract surgery

It is very uncertain whether NSAID changes visual improvement at end of treatment, as defined by two or more… compared with placebo or active control (very low certainty).

1 finding from 1 review

NSAIDs vs active control

Visual improvement at end of treatment, as defined by two or more Snellen lines · participants with acute or chronic CME following cataract surgery

It is very uncertain whether NSAID changes visual improvement at end of treatment, as defined by two or more… compared with active control (very low certainty).

1 finding from 1 review

NSAIDs vs placebo

Visual improvement at end of treatment, as defined by two or more Snellen lines · participants with chronic CME (≥ 4 months) following cataract surgery

It is very uncertain whether NSAID changes visual improvement at end of treatment, as defined by two or more… compared with placebo (very low certainty).

1 finding from 1 review

Interventions for involving patients in decision‐making about their health care vs usual care

Depression (6 months or more) MADRS measured 6 months after intervention (Aljumah 2015). PHQ‐9 measured 6 months after intervention (LeBlanc 2015). QIDS‐J measured 6 months after intervention (Aoki 2019a). Hospital Anxiety and Depression Scale (HA... · patients with mental health disorders
1 finding from 1 review

Interventions for involving patients in decision‐making about their health care vs usual care

Patient readmissions · patients with mental health disorders

It is very uncertain whether shared decision‐making interventions changes readmission (6 months or more) Rehospitalisation at 8 months after… compared with usual care (very low certainty).

1 finding from 1 review

Rituximab vs intravenous methylprednisolone

CAS improvement (decrease) by 2 or more points · thyroid‐associated ophthalmopathy

Summary of findings table ‐ Rituximab showed no clear difference in CAS improvement (decrease) by 2 or more points compared with intravenous methylprednisolone (low certainty).

1 finding from 1 review

Rituximab vs placebo

Proptosis improvement (decrease) by 2 mm or more · thyroid‐associated ophthalmopathy

It is very uncertain whether summary of findings table ‐ Rituximab changes proptosis improvement (decrease) by 2 mm or more compared with placebo (very low certainty).

1 finding from 1 review

Rituximab vs intravenous methylprednisolone

NOSPECS improvement (decrease) by 2 classes or more · thyroid‐associated ophthalmopathy

It is very uncertain whether summary of findings table ‐ Rituximab changes NOSPECS improvement (decrease) by 2 or more classes compared with intravenous methylprednisolone (very low certainty).

1 finding from 1 review

Rituximab vs intravenous methylprednisolone

Proptosis improvement (decrease) by 2 mm or more · thyroid‐associated ophthalmopathy

It is very uncertain whether summary of findings table ‐ Rituximab changes proptosis improvement (decrease) by 2 mm or more compared with intravenous methylprednisolone (very low certainty).

1 finding from 1 review

Rituximab vs intravenous methylprednisolone

Palpebral aperture improvement (decrease) by 3 mm or more · thyroid‐associated ophthalmopathy

It is very uncertain whether summary of findings table ‐ Rituximab changes palpebral aperture improvement (decrease) by 3 mm or more compared with intravenous methylprednisolone (very low certainty).

1 finding from 1 review

Rituximab vs intravenous methylprednisolone

Motility improvement (increase) by 1 class or more · thyroid‐associated ophthalmopathy

It is very uncertain whether summary of findings table ‐ Rituximab changes motility improvement (increase) by 1 class or more compared with intravenous methylprednisolone (very low certainty).

1 finding from 1 review